Ontology highlight
ABSTRACT:
SUBMITTER: Lamb YN
PROVIDER: S-EPMC8536603 | biostudies-literature | 2021 Sep
REPOSITORIES: biostudies-literature
Targeted oncology 20210901 5
Activating mutations in the epidermal growth factor receptor (EGFR) gene have been identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso<sup>®</sup>) is an orally administered, third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that is widely approved for the first-line treatment of advanced NSCLC with activating EGFR mutations. In the pivotal phase III FLAURA trial, osimertinib significantly prolonged progression-free survival (PFS) and overall ...[more]